Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349117 | 0.91 | KMT2A (0.46) | PPARGPPARAALDH1A1KMT2AMEN1 | |
| SCHEMBL349501 | 0.89 | ALDH1A1 (0.52) | PPARGPPARAALDH1A1KMT2AMEN1 | |
| SCHEMBL347672 | 0.86 | CYP3A4 (0.53) | ALDH1A1KMT2AMEN1HPGDHTT | |
| SCHEMBL350012 | 0.85 | HTT (0.44) | ALDH1A1KMT2AMEN1HPGDHTT | |
| SCHEMBL347866 | 0.85 | PPARG (0.52) | PPARGPPARAALDH1A1KMT2AMEN1 | |
| SCHEMBL348004 | 0.85 | TTR (0.53) | ALDH1A1KMT2AMEN1HTTMAPT | |
| SCHEMBL2283432 | 0.85 | KMT2A (0.48) | ALDH1A1KMT2AMEN1HTTMAPT | |
| SCHEMBL13521899 | 0.84 | HTT (0.47) | ALDH1A1KMT2AMEN1HTTMAPT | |
| SCHEMBL347720 | 0.84 | HTT (0.47) | ALDH1A1KMT2AMEN1HTTMAPT | |
| SCHEMBL347221 | 0.84 | LCK (0.54) | ALDH1A1KMT2AMEN1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271879-A1 | METHOD FOR PRODUCING PRODUCTS BASED ON WOOD AS A RAW MATERIAL | MM BOARD & PAPER GmbH (AT) | 2023-11-08 | — | — | EP | claimed |
| WO-2022144176-A1 | METHOD FOR PRODUCING PRODUCTS BASED ON WOOD AS A RAW MATERIAL | MM BOARD & PAPER GMBH (AT) | 2022-07-07 | — | — | WO | claimed |
| EP-4023812-A1 | METHOD FOR PRODUCING WOOD-BASED PRODUCTS | MM BOARD & PAPER GmbH (AT) | 2022-07-06 | — | — | EP | claimed |
| EP-4023813-A1 | METHOD FOR PRODUCING WOOD-BASED PRODUCTS | Technische Universität Wien (AT) | 2022-07-06 | — | — | EP | claimed |
| EP-2181818-A2 | Method for manufacturing wood fibre substances and wood fibre substances with lower emissions of volatile VOC | IHD Institut für Holztechnologie Dresden gGmbH (DE) | 2010-05-05 | — | — | EP | claimed |
| EP-4271879-A1 | METHOD FOR PRODUCING PRODUCTS BASED ON WOOD AS A RAW MATERIAL | MM BOARD & PAPER GmbH (AT) | 2023-11-08 | — | — | EP | disclosed |
| EP-4271880-A1 | METHOD FOR PRODUCING PRODUCTS BASED ON WOOD AS A RAW MATERAL | MM BOARD & PAPER GmbH (AT) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022144377-A1 | METHOD FOR PRODUCING PRODUCTS BASED ON WOOD AS A RAW MATERAL | MM BOARD & PAPER GMBH (AT) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022144176-A1 | METHOD FOR PRODUCING PRODUCTS BASED ON WOOD AS A RAW MATERIAL | MM BOARD & PAPER GMBH (AT) | 2022-07-07 | — | — | WO | disclosed |
| EP-4023812-A1 | METHOD FOR PRODUCING WOOD-BASED PRODUCTS | MM BOARD & PAPER GmbH (AT) | 2022-07-06 | — | — | EP | disclosed |
| EP-4023813-A1 | METHOD FOR PRODUCING WOOD-BASED PRODUCTS | Technische Universität Wien (AT) | 2022-07-06 | — | — | EP | disclosed |
| US-8247602-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2307362-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010003120-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PPARG 35/4885PPARA 133/4885ALDH1A1 2185/4885 |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | PPARG 35/4885PPARA 133/4885ALDH1A1 2185/4885 |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | PPARG 24/4885PPARA 86/4885ALDH1A1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.